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Background: Contrast induced nephropathy (CIN) is defined as an absolute increase in serum creatinine of 0.5 mg/dL or a relative increase in the 
serum creatinine of > 25% within 48 hours after percutaneous coronary intervention (PCI). We aimed to define the incidence and risk factors for CIN 
in a large primary PCI randomized control trial, HORIZONS-AMI.
Methods: We analyzed the rates of CIN in the entire cohort, and in chronic kidney disease (CKD) and non-CKD subgroups. To identify predictors of 
CIN, baseline demographic information, medications, historical characteristics, randomization group, procedural and angiographic characteristics 
were entered into a multivariable linear regression model using stepwise selection with entry stay criteria of 0.1/0.1. Analyses were conducted using 
SAS software, with a p value of < 0.05 in the final output deemed significant.
Results: CIN occurred in 15.5% of total patients (460/2970). A higher percentage of patients with CKD compared to those without CKD suffered 
CIN [18.9% (93/491) vs. 14.8% (367/2479), OR 1.28 (1.04-1.57), p = 0.021]. Risk factors identified for CIN appear below. There were no 
significant differences between rates of CIN by type of contrast used, low osmolar vs. isoosmolar (15.3% vs. 14.3%, RR 1.07 (0.82-1.38), p = NS). 
Patient Group (# CIN/# in model) Risk Factor Odds Ratio (95% CI), P Value
All Patients Contrast Volume 1.02 (1.01-1.03), p = 0.0004
LAD Disease 1.30 (1.01-1.67), p = 0.045
(392/2196) Age 1.31 (1.19-1.45), p < 0.0001
Diabetes Mellitus 1.39 (1.05-1.84), p = 0.021
Anemia 1.41 (1.02-1.96), p = 0.037
Killip Class 1.43 (1.02-2.00), p = 0.037
CHF 1.72 (1.00-2.95), p = 0.045
Final TIMI 3 Flow 0.70 (0.52-0.93), p = 0.016
Baseline Aspirin 0.73 (0.56-0.97), p = 0.027
Patients without CKD Contrast Volume 1.02 (1.01-1.03), p = 0.002
(360/2446) Age 1.42 (1.27-1.59), p < 0.0001
Killip Class 2-4 1.45 (1.00-2.10), p = 0.049
Patients with CKD Contrast Volume 1.03 (1.00-1.06), p = 0.027
(76/411) Age 1.48 (1.02-2.13), p = 0.037
Anemia 2.06 (1.15-3.71), p = 0.015
Current Smoker 2.47 (1.28-4.24), p = 0.007
Baseline Insulin 3.87 (1.57-9.55), p = 0.003
Family History Premature CAD 0.29 (0.12-0.73), p = 0.009
Final TIMI 3 Flow 0.42 (0.22-0.79), p = 0.008
Conclusions:  CIN occurs at a high incidence in primary PCI, both in patients with and without baseline CKD. Identification of predictive factors 
can promote the employment of preventive strategies in high-risk patients.
